627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I

Daratumumab for relapsed refractory primary effusion lymphoma plasmablastic lymphoma and multicentric castleman disease

Trial in progress Treatment of CNS lymphoma with zanubrutinib and tislelizumab A phase ib II investigator initiated study

Safety characteristics of brentuximab vedotin among patient subgroups Insightsfrom pooled clinical trial database

Mitoxantrone hydrochloride liposome based CMOP±R regimen achieves superior response in treatment Naïve non Hodgkin lymphoma A phase III clinical trial with matching adjusted indirect comparison

Polatuzumab vedotin retains potent activity against CD79B mutations Preclinical and clinical efficacy in diffuse large B cell lymphoma

First line selinexor plus R CHOP for high risk GCB subtype diffuse large B cell lymphoma A multi center single arm Phase II trial

Efficacy and safety of R CDOP in treatment Naïve non Hodgkin lymphoma with high tumor burden A multicenter prospective study

R cmop and pola R CMP regimens as first line treatment for diffuse large B cell lymphoma with cardiac comorbidity A prospective single arm multicenter study

Mitoxantrone hydrochloride liposome gemcitabine vinorelbine with or without anti CD20 antibody GVM±CD20 in patients with relapsed or refractory aggressive non Hodgkin s lymphoma A prospective multicenter Phase ? study

Phase 2 trial of polatuzumab vedotin rituximab and dose attenuated CHP in patients 75 years and older with large B cell lymphoma

Phase 2 Study of polatuzumab vedotin zanubrutinib and rituximab Pola ZR in untreated elderly and frail DLBCL patients Molecular features and follow up updates

The preliminary results of MRG001 C002 A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B cell lymphoma R R DLBCL

Orelabrutinib rituximab and thiotepa ORT in combination with or without high dose methotrexate in untreated primary central nervous system lymphoma

Preliminary results from a phase 1 1b first in human study of BGB 21447 a next generation BCL2 inhibitor in patients with B cell non Hodgkin lymphoma

Lessons from the IELSG45 trial The impact of patient fitness on dropout rate in primary central nervous system lymphoma PCNSL studies

Zanubrutinib in combination with R CHOP for previously untreated mcd type of Diffuse large b cell lymphoma DLBCL

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B cell lymphoma with CD30

First results of the methoglu Trial a phase 1 Trial from the LOC network evaluating the reduction of the time interval between methotrexate perfusions combined with glucarpidase in relapsed primary CNS lymphomas